(Finance) – Novavax has registered total revenue for the second quarter of 2022 equal to $ 186 million, compared to $ 298 million for the comparable period of 2021. The net loss was $ 510 million, compared to $ 352 million for the same period in 2021. Cash and cash equivalents amounted to $ 1.4 billion as of June 30, 2022, compared to $ 1.5 billion as of December 31, 2021.
The US biotechnology company has revised downward guidance on total revenue for the full year 2022 in a frog of $ 2 to $ 2.3 billion, compared to the previous forecast of $ 4-5 billion, also because he does not expect further sales of his COVID-19 vaccine this year in the United States in the face of an excess of global supply and weak demand.
The company has provided over 73 million doses of Nuvaxovid and Covovax globally to date, including 23 million doses since the beginning of the third quarter of 2022. The vaccine has been authorized last month for use among adults in the United States. However, only 7,381 doses of Novavax vaccine have been administered in the country so far, according to the latest government data.